Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

NCT06062537 · tracked via the Priya Life Science France tracker

Sponsor

Intergroupe Francophone du Myelome

Phase

Observational

Started

2023-09-19

Last updated

2026-04-13

Condition(s) studied

Multiple Myeloma

Study summary

200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria.

This is a multicenter, prospective, observational study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult patient (≥18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose) Exclusion Criteria: * Patients alive at the start of the study who did not receive study information or who objected to the collection of data * Patients who received teclistamab as part of an interventional clinical trial * Patients who are initiating teclistamab as part of a current interventional clinical trial

Primary outcome measure(s)

overall response rate (ORR) of teclistamab according to IMWG criteria — 6 months
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.
overall response rate (ORR) of teclistamab according to IMWG criteria — 24 months
ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.

Trial sites (31)

Facility	City	Region
CHU Amiens Picardie	Amiens	France
CH d'ANNECY	Annecy	France
Centre hospitalier d'Argenteuil	Argenteuil	France
Hopital de la cote Basque	Bayonne	France
CHU de Besançon	Besançon	France
CHU Bordeaux	Bordeaux	France
Centre hospitalier de Brive-la-Gaillarde	Brive-la-Gaillarde	France
CHU CAEN	Caen	France
Centre hospitalier Métropole de Savoie	Chambéry	France
CHU Clermont-Ferrand Site Estaing	Clermont-Ferrand	France
CHU Henri Mondor	Créteil	France
Chu Dijon	Dijon	France
CH Dunkerque	Dunkirk	France
CHU de Lille	Lille	France
Groupe hospitalier Bretagne Sud	Lorient	France
Institut Paoli Calmette	Marseille	France
CH de METZ	Metz	France
CHU Saint-Eloi - CHU de Montpellier	Montpellier	France
Chu de Nantes	Nantes	France
CHU de Nice	Nice	France
Hopital Necker	Paris	France
Hopital saint louis	Paris	France
CH Perpignan	Perpignan	France
Hopital Novo	Pontoise	France
Chu de Rennes	Rennes	France
Centre Henri Becquerel	Rouen	France
Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne	Saint-Priest-en-Jarez	France
Hopital de Hautepierre	Strasbourg	France
CHU Toulouse	Toulouse	France
CHU de Tours	Tours	France
CH Bretagne Atlantique	Vannes	France

More Intergroupe Francophone du Myelome trials in France

MInimal Residual Disease Adapted Strategy Active, not recruiting

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. Active, not recruiting

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma Active, not recruiting

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Recruiting

Other trials for the same condition

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Active, not recruiting

MInimal Residual Disease Adapted Strategy Active, not recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Active, not recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06062537 on ClinicalTrials.gov ↗ ← All trials in France